Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4381060 | 0.90 | TP53 (0.37) | PKMMEN1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL4383060 | 0.90 | NAMPT (0.41) | PKMMEN1KMT2AGAASMN1; SMN2 | |
| SCHEMBL4383813 | 0.86 | RORC (0.43) | PKMMEN1KMT2ATDP1SMN1; SMN2 | |
| SCHEMBL4385274 | 0.85 | PKM (0.41) | PKMMEN1KMT2AGAASMN1; SMN2 | |
| SCHEMBL4385346 | 0.82 | MEN1 (0.43) | MEN1KMT2AGAASMN1; SMN2 | |
| SCHEMBL4381306 | 0.79 | TEK (0.42) | MEN1KMT2AGAASMN1; SMN2LMNA | |
| SCHEMBL4380375 | 0.79 | CCR6 (0.45) | SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL13589008 | 0.79 | KMT2A (0.42) | KMT2APOLBSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL4383772 | 0.78 | ATM (0.42) | PKMGAASMN1; SMN2LMNAL3MBTL1 | |
| SCHEMBL4384476 | 0.77 | ALDH1A1 (0.47) | MEN1KMT2ASMN1; SMN2LMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2009-12-03 | — | — | US | disclosed |
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2009-12-03 | — | — | US | disclosed |
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | KCNN4, CACNA1A, KCNN3 | PKM 2106/4885MEN1 3694/4885KMT2A 2079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.